Filter Results
Clinical Studies
Results filtered:Study status:
Open
Contact Us for the Latest Status
Closed for Enrollment
Open
-
A Phase III Trial Of One Vs. Two Years Of Maintenance Olaparib, With Or Without Bevacizumab, In Patients With BRCA1/2 Mutated Or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response To First Line Platinum Based Chemotherapy
Scottsdale/Phoenix, Ariz.,
Rochester, Minn.
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5\'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.
-
A Randomised, Open-Label, Phase III Study Of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy Or Plus Camizestrant For The First-Line Treatment Of Patients With BRCA1, BRCA2, Or PALB2 Mutations And Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
Rochester, Minn.
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer.
-
An Open-Label, Multicenter Study To Investigate The Safety, Tolerability, Pharmacokinetics, And Preliminary Efficacy Of XL309 (ISM3091) As Single-Agent And Combination Therapy In Patients With Advanced Solid Tumors
Jacksonville, Fla.,
Rochester, Minn.
This is a FIH, multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as PK and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in subjects with advanced solid tumors.
-
MC1733, Phase I Trial of intratumoral administration of a measles virus derivative expressing the Helicobacter pylori neutrophil-activating protein (NAP) (MV-s-NAP) in patients with metastatic breast cancer
Rochester, Minn.
To determine the maximally tolerated dose (MTD) of intratumoral administration of an Edmonston strain measeles virus genetically engineered to express NAP (MV-s-NAP) in patients with metastatic breast cancer; to determine the safety and toxicity of on-time and serial administration of MV-s-NAP in patients with metastic breast cancer.
-
Phase 1/1b Study Of The Safety, Pharmacokinetics, Pharmacodynamics And Preliminary Clinical Activity Of Lunresertib Alone Or In Combination With RP-3500 Or Debio 0123 In Patients With Advanced Solid Tumors
Jacksonville, Fla.,
Rochester, Minn.
The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.
-
Phase 1/2 Study Of PARG Inhibitor ETX-19477 In Patients With Advanced Solid Malignancies
Scottsdale/Phoenix, Ariz.,
Jacksonville, Fla.,
Rochester, Minn.
The purpose of this study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.
-
Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
Rochester, Minn.
This research is being done to evaluate the safety and tolerability of the new drug, axatilimab, in combination with olaparib (a standard of care treatment) in Breast Cancer 1/2 genes (BRCA 1/2) and PALB2 associated HER2-negative metastatic breast cancer.
The names of the study drugs involved in this study are:
* Axatilimab (a type of antibody)
* Olaparib (a type of PARP inhibitor)
Contact Us for the Latest Status
-
A Randomised, Open-Label, Phase III Study Of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy Or Plus Camizestrant For The First-Line Treatment Of Patients With BRCA1, BRCA2, Or PALB2 Mutations And Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
Jacksonville, Fla.
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer.
Closed for Enrollment
-
A Study on the Feasibility of Investigating Associations between Environmental Exposures and Breast Cancer Risk among School Employees
Rochester, Minn.
The purpose of this study is to conduct exploratory comparisons of 1) the environmental exposures of the cases and controls through numerous methodologies including metal analysis, metabolomics, and exposomics. Samples collected will include hair, nails, blood, and urine.
-
An Open-Label, Multicenter Study To Investigate The Safety, Tolerability, Pharmacokinetics, And Preliminary Efficacy Of XL309 (ISM3091) As Single-Agent And Combination Therapy In Patients With Advanced Solid Tumors
Scottsdale/Phoenix, Ariz.
This is a FIH, multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as PK and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in subjects with advanced solid tumors.
-
Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients With Molecularly Selected Cancers (ATTACC) (ATTACC)
Rochester, Minn.,
Jacksonville, Fla.,
Scottsdale/Phoenix, Ariz.
The primary purpose of this study is to assess the safety and tolerability of Niraparib or Olaparib in combination with RP-3500, in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-3500 in combination with Niraparib or Olaparib, examine pharmacokinetics (PK) and assess anti-tumor activity.
.